Ascendis Pharma Says FDA Granted Orphan Drug Exclusivity To YORVIPATH For Treatment Of Hypoparathyroidism In Adults
Portfolio Pulse from Benzinga Newsdesk
Ascendis Pharma announced that the FDA has granted Orphan Drug Exclusivity to YORVIPATH, a treatment for hypoparathyroidism in adults. This exclusivity is significant for the company as it targets a rare disease affecting 70,000 to 90,000 people in the US.
September 11, 2024 | 9:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendis Pharma's YORVIPATH has been granted FDA Orphan Drug Exclusivity for treating hypoparathyroidism, a rare disease. This exclusivity could enhance the company's market position and revenue potential.
The FDA's Orphan Drug Exclusivity for YORVIPATH is a significant regulatory milestone for Ascendis Pharma, as it provides market exclusivity for a rare disease treatment. This can lead to increased market share and revenue, positively impacting ASND's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100